{
    "nctId": "NCT03323424",
    "briefTitle": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers",
    "officialTitle": "Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (IRAM)",
    "overallStatus": "WITHDRAWN",
    "conditions": "Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Survival rate without progression for patients with metastatic breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with a metastatic breast adenocarcinoma HER2+, a metastatic squamous carcinoma of VADS, or a colorectal adenocarcinoma with a wild status for RAS (NRAS and KRAS)\n* Patient presenting at least two measurable metastases (according to the RECIST v1.1 criteria):\n* At least one eligible to SBRT (hepatic, pulmonary, bone or intra-cranial metastasis, with a diameter between 1 and 4cm)\n* At least one non irradiated measurable metastasis\n* Performance Status corresponding to 0, 1, or 2\n* Realisation of a PET (Positron Emission Tomography)-Scanner and a TAP (Thoraco-AbdominoPelvic)-Scanner 30 days maximum before inclusion\n* Informed consent patient\n* Patients affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Patient presenting a known non-indication or contraindication to the first line treatment administered\n* Pregnant or nursing women\n* Patient with an another cancer during the 5 last years, excepting basocellular carcinoma, and skin epidermoid carcinoma\n* Patient presenting a non-controlled pain linked to the cancer\n* Patient presenting a non-controlled hypercalcemia or symptomatic hypercalcemia needing an ongoing use of bisphosphonates or denosumab.\n* Patient presenting an inflammatory pathology or active autoimmune pathology or history of.\n* Patient having received one or more vaccines during the 4 weeks preceding the beginning of the systemic treatment.\n* Patient currently using corticosteroids or other immune-suppressors during the two weeks before inclusion, and any other situation where this kind of treatments could be necessary during the study.\n* Patient deprive of liberty or under administrative supervision, patients with an impossible take care supervision for psychological or geographical reasons.\n* Stereotactic Body Radio-Therapy (SBRT) must not include metastases localized in the 3 centimeters of the structure previously irradiated.\n* Patient presenting serious active comorbidities defined by the protocol.\n* Known seropositivity to the HIV",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}